Molecular Partners AG (MOLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Molecular Partners AG (MOLN) has a cash flow conversion efficiency ratio of -0.099x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-9.49 Million ≈ $-12.00 Million USD) by net assets (CHF95.53 Million ≈ $120.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Molecular Partners AG market capitalisation for the company's overall valuation and market capitalisation.
Molecular Partners AG - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Molecular Partners AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Molecular Partners AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Partners AG ranked by their cash flow conversion efficiency. Explore Molecular Partners AG (MOLN) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avantium Holding BV
AS:AVTX
|
-0.112x |
|
Cegedim S.A.
PA:CGM
|
0.260x |
|
Tekna Holding AS
OL:TEKNA
|
0.062x |
|
Castles Technology Co Ltd
TW:5258
|
0.095x |
|
KHVATEC Co.Ltd
KQ:060720
|
0.116x |
|
TEMC Co. Ltd.
KQ:425040
|
-0.021x |
|
Seoul City Gas
KO:017390
|
-0.022x |
|
LVMC Holdings
KO:900140
|
0.022x |
Annual Cash Flow Conversion Efficiency for Molecular Partners AG (2013–2024)
The table below shows the annual cash flow conversion efficiency of Molecular Partners AG from 2013 to 2024. View MOLN live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF141.64 Million ≈ $179.07 Million |
CHF-59.25 Million ≈ $-74.91 Million |
-0.418x | -25.08% |
| 2023-12-31 | CHF176.43 Million ≈ $223.05 Million |
CHF-59.01 Million ≈ $-74.60 Million |
-0.334x | -166.33% |
| 2022-12-31 | CHF235.17 Million ≈ $297.31 Million |
CHF118.57 Million ≈ $149.90 Million |
0.504x | +159.47% |
| 2021-12-31 | CHF107.29 Million ≈ $135.64 Million |
CHF-90.95 Million ≈ $-114.99 Million |
-0.848x | -213.61% |
| 2020-12-31 | CHF107.22 Million ≈ $135.56 Million |
CHF-28.98 Million ≈ $-36.64 Million |
-0.270x | -1130.82% |
| 2019-12-31 | CHF54.14 Million ≈ $68.45 Million |
CHF-1.19 Million ≈ $-1.50 Million |
-0.022x | +95.26% |
| 2018-12-31 | CHF91.70 Million ≈ $115.94 Million |
CHF-42.47 Million ≈ $-53.70 Million |
-0.463x | -35.09% |
| 2017-12-31 | CHF116.73 Million ≈ $147.58 Million |
CHF-40.02 Million ≈ $-50.60 Million |
-0.343x | -31.60% |
| 2016-12-31 | CHF135.79 Million ≈ $171.68 Million |
CHF-35.38 Million ≈ $-44.73 Million |
-0.261x | -249.27% |
| 2015-12-31 | CHF151.79 Million ≈ $191.91 Million |
CHF26.50 Million ≈ $33.50 Million |
0.175x | +328.68% |
| 2014-12-31 | CHF148.48 Million ≈ $187.72 Million |
CHF-11.33 Million ≈ $-14.33 Million |
-0.076x | +72.91% |
| 2013-12-31 | CHF48.32 Million ≈ $61.08 Million |
CHF-13.61 Million ≈ $-17.21 Million |
-0.282x | -- |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more